ArticleBMC cancer2014
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.Oncotarget · 2017Pooled it
- Association ofInternational journal of molecular sciences · 2026Article
- Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.Journal of translational medicine · 2024Review
- Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.Frontiers in cell and developmental biology · 2023Article
- A high preoperative serum IL-25 level is a negative prognosis predictor after liver resection for HBV-HCC.Frontiers in oncology · 2022Article
- Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers.Frontiers in immunology · 2022Review
- Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype.Clinical and experimental medicine · 2020Article
- Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.BJS open · 2020Article
- Preoperative Serum IL6, IL8, and TNF-Gastroenterology research and practice · 2019Article
- Article
- Bone morphogenetic protein and activin membrane-bound inhibitor overexpression inhibits gastric tumor cell invasion via the transforming growth factor-β/epithelial-mesenchymal transition signaling pathway.Experimental and therapeutic medicine · 2018Article
- Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.Oncotarget · 2018Article
- Expression of Th17/Treg related molecules in gastric cancer tissues.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Interleukin-6 Genetic Variation and Susceptibility to Gastric Cancer in an Iranian PopulationAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.Pharmaceutics · 2017Review
- Article
- STAT3 in the systemic inflammation of cancer cachexia.Seminars in cell & developmental biology · 2016Review
- Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.Biochimica et biophysica acta · 2015Article
- Genetics and gastric cancer susceptibility.International journal of clinical and experimental medicine · 2015Review
- Genetic polymorphisms of IL-6 and IL-10 genes correlate with lung cancer in never-smoking Han population in China.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade. The prognostic role of the functional IL-6 (promoter) rs1800795 and the IL-6R (receptor) rs8192284 single nucleotide polymorphisms (SNP) was studied in patients with advanced gastric cancer treated with palliative chemotherapy.
methodsOne-hundred-sixty-one patients were genotyped for rs1800795 and rs8192284 SNPs using polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis assay. These results were studied for association with overall survival (OS).
resultsIn 161 assessable patients, frequencies of rs1800795 G/G, G/C and C/C genotypes were 46%, 42% and 12%, respectively. Frequencies of rs8192284 A/A, A/C and C/C genotypes were 36%, 45% and 19%, respectively. Carriers of the rs1800795 G/G and rs8192284 C/C genotypes showed the worst OS. In the multivariate model, rs1800795 G/G (1.69 hazard ratio; 95% confidence interval 1.18-2.42), and rs8192284 C/C (1.78 hazard ratio; 95% confidence interval 1.12-2.83) confirmed an adverse prognostic impact.
conclusionsIn this population, genetic variants that up-regulate the IL-6 system showed impact on OS. This findings sustain the hypothesis that anti-IL-6 compounds deserve clinical studies as novel therapeutics in the palliative treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.